Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

Background and aims:This study evaluates the long-term safety of infliximab in patients with inflammatory bowel disease (IBD) treated with the drug over a 14-year period.Methods:The medical records of 734 patients with IBD treated with infliximab and 666 control patients not treated with infliximab...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2009-04, Vol.58 (4), p.501-508
Hauptverfasser:	Fidder, H, Schnitzler, F, Ferrante, M, Noman, M, Katsanos, K, Segaert, S, Henckaerts, L, Van Assche, G, Vermeire, S, Rutgeerts, P
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Age Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Autoimmune diseases Autoimmune Diseases - chemically induced Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Clinical trials Drug dosages Drug Eruptions - etiology Drug Evaluation Endoscopy Female Follow-Up Studies Gastroenterology. Liver. Pancreas. Abdomen Gastrointestinal Agents - adverse effects Gastrointestinal Agents - therapeutic use Gender Hospitals Humans Immunoglobulins Immunomodulators Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Infections Inflammatory bowel disease Inflammatory Bowel Diseases - drug therapy Infliximab Lupus Male Medical sciences Mortality Neoplasms - chemically induced Opportunistic Infections - chemically induced Other diseases. Semiology Pharmacology. Drug treatments Retrospective Studies Skin Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!